MedTrace Logo

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

NCT07238322 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 253

Last updated 2026-05-15

No results posted yet for this study

Summary

This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).

Conditions

  • Retrospective Study
  • Glioma
  • Brain Neoplasms

Interventions

DIAGNOSTIC_TEST

18F(FET)PET

Imaging as part of routine care

Sponsors & Collaborators

  • Telix Pharmaceuticals (Innovations) Pty Limited

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-22
Primary Completion
2026-01-23
Completion
2026-01-23

Countries

  • United States
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07238322 on ClinicalTrials.gov